Pharmacokinetic studies of estradiol enantate in menopausic women.
Healthy menopausic women received 10 mg i.m. of estradiol enantate (estra-1,3,5(10)-triene-3-ol-17 beta-heptanoate, one of the components of Perlutal or Topasel). Their estradiol serum levels were determined by radioimmunoassay (RIA) on days 1, 2, 3, 6, 8, 10, 13, 15, 17, 20, 22, 24, 27, 29 and 31 after the injection. Based on these data, the elimination rate constant (K = 0.12445 d-1), the elimination half-life (t1/2 = 5.57 d), the absorption rate constant (Kabs. = 1.5050 d-1), the absorption half-life (t1/2 abs. = 0.46 d) and the volume of distribution (Vd = 5087 l) were calculated. These results are compared with others not obtained by RIA and discussed from a therapeutic-clinical point of view.
D004958:Estradiol / Q000031:analogs & derivatives* / Q000097:blood / Q000378:metabolism; D005260:Female; D006207:Half-Life; D006801:Humans; D007408:Intestinal Absorption; D007700:Kinetics; D008593:Menopause / Q000378:metabolism*; D008875:Middle Aged; D011863:Radioimmunoassay
D004958:Estradiol; C002027:estradiol enanthate